| | | | |
|---|---|---|---|
| **Name of Company:**<br>Boehringer Ingelheim | | **Statement on discontinuation of the study** |  |
| **BI Proprietary Name: n.a** | | **EudraCT No.:**<br>2008-000343-33 | |
| **BI Investigational Product:**<br>Pramipexole (Mirapex®, Mirapexin®, Pexola®, Sifrol®) | | **Page:**<br>1 | |
| **Report Date:**<br>NA | **Trial No. / Doc. No.:**<br>248.641 | **Dates of Trial:**<br>NA | **Date of Revision:**<br>NA |

**Proprietary confidential information**
**© 2018 Boehringer Ingelheim International GmbH or one or more of its affiliated companies. All rights reserved.**
This document may not - in full or in part - be passed on, reproduced, published or otherwise used without prior written permission

| | |
|---|---|
| **Title of Trial:** | A Phase III double-blind, double-dummy, placebo-controlled, 8 week fixed dose trial with pramipexole IR (Mirapex®, Mirapexin®, Pexola®, Sifrol®) 0.125 and 0.5 mg/day administered orally to investigate the efficacy and safety in patients 6-17 years of age diagnosed with Tourette Syndrome according to DSM-IV criteria |
| **Trial Sites:** | NA |
| **Publications:** | NA |
| **Clinical Phase:** | III |
| **Statement on discontinuation of the study:** | Discontinued by Boehringer Ingelheim during preparation of trial. No patient entered the study, therefore no results data available. |